Using a Synthetic CB2-Targeting Compound to Target Neuroinflammation in the Brain, Mitigating Alzheimer’s Disease
Time: 2:00 pm
day: Day Two
Details:
- Keeping up with the evolving translational models of CB2-targeting compounds
- Understanding the pathways behind CB2-targeting to treat the neurological symptoms of AD through microglial-mediated neuroinflammation
- Preclinical and clinical research of a candidate compound, NTRX-07, that can readily penetrate the brain and modulate microglial activity via the CB2 receptor
- Exploring possible synergistic effects of NTRX-07 with other therapies used in the treatment paradigm
